Abstract

SCH 39166 [(—)- trans-6,7,7 a,8,9,13b-hexahydro-3-chloro-2-hydroxy- N-methyl-5H-benzo(d)naphtho-(2,1- b)azepine] is a new more selective dopamine D-1 receptor antagonist than the widely used SCH 23390. [ 11C]SCH 39166 was prepared by N-methylation of the desmethyl compound SCH 40853 [(—)- trans-6,7,7 a,8,9,13b-hexahydro-3-chloro-2-hydroxy-5H-benzo(d)naphtho-(2,1-b)azepine] with [ 11C]methyl iodide. Reaction in acetone with subsequent straight-phase semi-preparative HPLC resulted in 20–30% radiochemical yield (from EOB and decay-corrected) with a total synthesis time of 35–40 min and a radiochemical purity >99%. The specific activity obtained at EOS was about 1500 Ci/mmol (55 GBq/μmol). [ 11C]SCH 39166 was injected into a Cynomolgus monkey. PET-analysis demonstrated accumulation in the striatum, a region known to have a high density of dopamine D-1 receptors. In a displacement experiment, radioactivity in the striatum was markedly reduced after injection of 6 mg unlabelled SCH 23390, thus demonstrating the specificity and reversibility of [ 11C]SCH 39166 binding to dopamine D-1 receptors.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.